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Abstract: Vascular endothelial growth factor (VEGF) is well established as the main agent responsible for vascular leakage and angiogenesis in the diabetic retina. While VEGF can have positive effects on hyperglycemia stressed retinal tissues, it also plays a role in events progressing to the oxygen-stressed, i.e. hypoxic, diabetic retina. Some VEGF makes its way to the retina from systemic
sources and some is produced locally within the eye. Hyperglycemia, oxidants, inflammation, and
advanced glycation end-products are all stimulants to VEGF production, both in the hypoxic and the
pre-hypoxic retina. Endothelial cells, pericytes, Müller cells, microglia, astrocytes, retinal pigment
epithelium and neurons have all been known to produce VEGF at some point in retinal development
or in disease. Excessive VEGF production in the early diabetic retina can lead to retinal exposure or
mechanisms which exacerbate further damage. While Müller cells are likely the most significant producer of VEGF in the pre-hypoxic retina, other VEGF producing cells may also play a role due to
their proximity to vessels or neurons. Study of the release of VEGF by retinal cells in hyperglycemia
conditions, may help identify targets for early treatment and prevent the serious consequences of diabetic retinopathy.
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1. INTRODUCTION
Vascular endothelial growth factor A (VEGF) is a potent
cytokine associated with cell-survival, mitogenesis of endothelial cells and vascular permeability [1-4]. It is found in
many different tissues of the body where, depending on its
concentration and balance with other cytokines, it can exert
either positive or deleterious effects [2]. In the retina, suppression of VEGF has been associated with apoptosis of
Müller cells (MC) and retinal neurons, including photoreceptors [5]. Recent evidence suggest anti-VEGF treatments may
result in reductions in super-oxide dismutase (SOD2) in
Muller cells, exposing retina to higher concentration of reactive oxygen species (ROS) [6, 7]. In humans, increased levels of hematologic VEGF have been linked to cancer, atherosclerosis, male smoking, leukocyte count, and decreased
HDL-concentration [8-10]. Elevated VEGF levels have been
linked to neovascular eye diseases such as diabetic retinopathy (DR) both in the early and late stages [11-13]. VEGF-B,
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a member of the VEGF family whose gene is located on
chromosome 11, has been found to function in the maintenance of newly formed vessels during pathologies, neurons
and control uptake of fatty acids into endothelial cells of the
heart and skeletal system [14].
The human VEGF (VEGF-A) gene is comprised of eight
exons in chromosome 6. Alternative splicing of this gene
results in VEGF molecules with different peptide lengths
including VEGF121, VEGF145, VEGF148, VEGF165, VEGF183,
VEGF189, and VEGF206 [15].
All VEGF isoforms contain peptides coded from exons
1-5 and 8 [15]. VEGF121 does not contain amino acids encoded by exons 6 and 7. Likewise, exon 6 does not code any
amino acids in VEGF165. While VEGF189 contains amino
acids coded by exons 1-8, VEGF206 has an extra 17 amino
acid residues encoded by exon 6 [15-17]. Of the 24 amino
acids common to VEGF189 and VEGF206 encoded by exon 6,
12 of these are basic amino acids. Exon 7 encodes 44 amino
acids in VEGF165, VEGF189 and VEGF206, 9 of these are basic. The shorter forms of VEGF are more acidic. VEGF165
and VEGF189 have 16 cysteines, whereas VEGF206 has 18,
© 2017 Bentham Science Publishers
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and VEGF121 only has 9 [16, 17]. While VEGF121 is soluble,
practically all VEGF189 and VEGF206 are bound to cell surfaces or the extracellular matrix (ECM). VEGF165 has solubility properties between VEGF121 and VEGF189 with 5070% of it bound to cell surfaces or the extracellular matrix
[4, 18]. Splice variants VEGF121, VEGF165, and VEGF189 are
the most abundant in humans [15, 16, 19]. Receptors for
VEGF are found mainly on endothelial, pericyte, and bone
marrow-derived cells [4, 20, 21]. VEGF receptor 1 (VEGFR1, Flt-1) binds VEGF-A, placental growth factor (PLGF),
and VEGF-B and has generally been considered to act as a
decoy receptor suppressing VEGF activity, but in some cases
it has been found to promote mitogenesis and to release
some tissue-specific growth factors [4, 22]. VEGFR-1 is
found in higher concentrations than VEGF receptor 2
(VEGFR-2, Flk-1) in retinal pericytes [23-25]. Due to its
primary role in mediating VEGF responses such as angiogenesis, permeability, and mitogenesis, VEGFR-2 is considered the functional VEGF receptor. Up-regulation of both
VEGF and VEGFR-2 mRNA and protein have been noted in
the inner retina of streptozotocin (STZ) induced diabetic rats
[26, 27]. VEGFR-3 plays a role in the development of vasculature, but in the adult it is found primarily in the lymphatic
endothelium [28]. Neurophilin 1 (NP1) and 2 (NP2) also
bind VEGF and appear to enhance the effects of VEGF binding to VEGFR-2. VEGF binding to NP-1 and 2 requires part
of exon 7, which is not present in VEGF121, thus explaining
the increased potency of VEGF165 compared to VEGF121 [4].
VEGF has different actions on retinal tissues depending
on the stage of DR [29]. Many different stimuli cause increased production of VEGF in the diabetic retina. It is the
goal of this review to discuss those, which occur in early
diabetes, i.e. the pre-hypoxic retina, before VEGF production mechanisms linked to hypoxia such as Hypoxia Inducible Factor (HIF-1) play a role. Many of these actions may
be harmful, but some can be protective such as VEGF protection of retinal neurons in early disease [30]. Hyperglycemia, oxidative stress, and inflammation can induce production of VEGF either from systemic sources or locally within
the eye [31]. It has been proposed that advanced glycation
end-product formation (AGE), activation of protein kinase C
(PKC) and oxidant formation can all be initiated by superoxide production from hyperglycemia through the mitochondrial election-transport chain [31, 32]. The early stages of
experimental DR require the manifestation of intercellular
adhesion molecule 1 (ICAM-1) along with VEGF for vascular effects to occur, thus implicating systemic sources of
VEGF in the initiation of DR [31]. In early and late diabetic
retinal disease, VEGF alters tight junctions between endothelial cells, resulting in increased vascular permeability exposing the retina to systemic sources of VEGF and increasing
the production of VEGF from retinal sources. As vessel
damage continues in the progression of DR, hypoxia can also
occur, contributing to ocular VEGF production. VEGF’s
mitogenic effects can result in neovascularization of the retina, i.e. proliferative diabetic retinopathy (PDR). VEGF is a
major, but not the only, factor in diabetic macular edema
(DME), which can occur at either the early or late stage of
DR [33].
VEGF is produced from many ocular and non-ocular
sources. Since long-term hyperglycemia enhances the release
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of VEGF in extra-ocular tissues, VEGF could arrive to the
eye via vascular perfusion. Oxidized low-density lipoproteins (oxLDL) and glycated albumins, both associated with
hyperglycemia, have been found to raise VEGF expression
from macrophages and renal glomeruli [34-37]. Increased
plasma levels of VEGF have also been correlated with Scone dysfunctions in a population of children and adults with
type 1 diabetes in which no visible signs of retinopathy were
yet present [38].
There is significant confusion as to the correlation of
plasma, serum and intraocular VEGF concentration. Wang et
al. report plasma levels of individuals with proliferative diabetic retinopathy to be 3.6x higher than controls and vitreous
levels to be 4.7x higher [39]. Burgos et al. found no differences in correlation between serum and vitreous VEGF concentrations in DR [40]. Debate has ensued over whether
soluble VEGF travels in blood plasma, or whether it is stored
in platelets [41]. Shlingemann et al. reported that platelets in
type 1 diabetes patients showed no difference in their state of
activation compared to normal controls. When platelet activation was inhibited during blood collection procedures, free
VEGF plasma levels were low in both patients with (6.1 ±
9.5 pg/mL) and without diabetes (6.1 ± 9.4 pg/mL) and did
not correlate with any diabetes markers. Using more traditional methods of blood collection, i.e. citrate, the plasma
contained significantly higher levels of VEGF in diabetic
patients (16.5 ± 12 pg/mL) than in normal controls (10.4 ±
4.9 pg/mL) and correlated with glycosylated hemoglobin
levels (A1c) [36]. This suggests that patients with diabetes
either carry a higher concentration of VEGF in their platelets
or that diabetic conditions cause the platelets to release more
VEGF. How this platelet stored VEGF is released to interact
with ocular tissues has not been well clarified.
While there can be debate as to how much VEGF arrives
in the retina from systemic sources much of the VEGF present in the eye during diabetes and the development of DR
comes from local VEGF production [11, 12, 42, 43]. Endothelial cells, pericytes, Müller cells, microglia, retinal pigment epithelium, and neurons have all been known to produce VEGF at some point in development of disease, although there is no evidence that neurons are a significant
producer of VEGF during diabetes (Fig. 1) [44]. It is interesting to note that while most studies of VEGF concentration
in the eye rely on vitreous and aqueous sampling, VelezMontoya et al. found in a study of retinopathy of prematurity
that sub-retinal concentrations of VEGF were 22x higher
than aqueous levels, 13.8x higher than vitreous levels, and
23.5x higher than plasma levels [45]. What is less clear is
where ocular VEGF production occurs in DR and actually
impacts retinal changes. Murata et al. report VEGF mRNA
markers were expressed in ganglion cells, glial cells such as
astrocytes and Muller cells, smooth muscle cells and pericytes in the vessel walls, and retinal pigment epithelium.
VEGF was found to be distributed along all layers of the
retina. However, VEGF was most prominently noted in the
nerve fiber layer [29]. Relevant factors influencing damage
in diabetes are the level of VEGF release and its proximity to
vessels, especially endothelial cells and pericytes.
In this review article, we summarize, for the first time,
major retinal sources of VEGF in the pre-hypoxic diabetic
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retina (Tables 1-4). This information is key to the understanding of early events in the etiology of DR caused by excessive VEGF. Detailed understanding of the origins and
action of VEGF at this stage will provide opportunities for
clinical interventions.
2. ENDOTHELIAL CELLS AND PERICYTES
Although VEGF has been found to target other cells including pericytes and some non-vascular cells, the primary
target of VEGF is the vascular endothelial cell [1, 5, 23].
Interacting together, pericytes and endothelial cells assemble
the vascular basement membrane [46-48]. Endothelial cells
surround the vascular lumen and are enclosed by pericytes
typically being only about 20 nm apart [47]. While endothelial cells are exposed to the vascular lumen, pericytes are
only associated with endothelial cells and the retinal capillary basement membrane [49]. Pericytes and endothelial
cells have several connections with each other including
pericyte cytoplasmic fingers inserted into endothelial cell
invaginations (peg-socket type), areas where the two cells
membranes come very close, and other areas where cytoplasmic filaments near the plasma membrane appear to be
associated with extracellular fibronectin plaques between the
two cells [47, 48]. These types of connections may vary in
different tissues, but in some cases may include as many as
1,000 pericyte contacts to a single endothelial cell [48]. A
single pericyte can partially cover several endothelial cells
[46]. The ratio of pericytes to endothelial cells in the inner
retinal capillaries is approximately 1:1; in the rat it is about
1:3 which is similar to rat cerebral capillaries, but significantly higher than other tissues such as skeletal muscle [4850]. Pericytes cover about 40% of the circumference of normal rat retinal capillaries [50].
Pericytes are more resistant to aging and ischemia than
endothelial cells. However, Kuwabara and Cogan note that
diabetes is the one disease where pericytes in the retina are
preferentially lost before endothelial cells [49]. In the diabetic retina a reduction of the pericyte-endothelial ratio has
been linked to increased endothelial cell proliferation, a
hallmark of PDR [49, 51]. Also, it has been proposed that
pericytes regulate capillary proliferation [47, 49, 52].
Paracrine and juxtacrine signaling between pericytes and
endothelial cells is required for vascular development and
maintenance and has been extensively explored [49]. Platelet-derived growth factor (PDGF-B) is released from endothelial cells and has been found to bind to pericyte surface
receptor platelet-derived growth factor receptor 
(PDGFR). Knockouts of PDGF or its receptor result in
pericyte deficiency. Collaboration between pericytes and
endothelial cells is required for vascular development and
maintenance [53]. Angiopoietin-1 (Ang-1) expressed by
pericytes and its endothelial cell receptor Tie-2 have also
been implicated in the development and maintenance of vasculature. Other cytokines such as heparin-binding epidermal
growth factor (HB-EGF), stromal-derived factor 1- (SDF1), chemokine C-X-C receptor 4 (CXCR4), sonic hedgehog
(Shh), neurogenic locus notch homolog protein 3
(NOTCH3), jagged-1 (JAG-1), ephrin and ephrin receptor
have also been found to play a role in endothelia-pericyte
crosstalk and vascular stability [48]. The juxtapositional
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properties of pericytes and endothelial cells are illustrated by
Erber et al. in which solid rat tumors implanted in athymic
mice experienced loss of mature and immature vessels when
VEGFR-2 and PDGFR- were blocked resulting in loss of
physical association between pericytes and their adjacent
vascular endothelial cells. When VEGFR-2 was blocked,
immature vessels quickly regressed, but in mature vessels
pericytes stabilized the vessels. Pericytes were recruited to
remaining immature vessels and increased expression of
other survival factors such as Ang-1. It was only when the
pericyte receptor PDGFR-  was also blocked that endothelial cells on mature vessels underwent apoptosis [54].
In normal physiological environments, endothelial cells
cultured alone have been found to secrete very little VEGF
[55]. No direct comparisons of VEGF production from different retinal cells in pre-hypoxic environments have been
carried out. In a hypoxic environment, Watkins et al. compared the response of Muller cells, retinal pigment epithelium (RPE), astrocytes and retinal microvascular endothelial
cells (EC) and found that endothelial cells contributed the
least VEGF into the cellular media. Hypoxic Muller cells
produced 140x more, RPE 10x more, and astrocytes produced 27x more secreted VEGF than EC [15]. When endothelial cultures were combined with pericyte precursors in a
co-culture system, pericytes were found to increase their
production of cell-associated VEGF and VEGF in the conditioned media [55]. Pericyte production of VEGF has also
been associated with endothelial cell stability during and
after vessel development [51, 55]. Endothelial cell proliferation is suppressed in cells grown in contact with pericytes,
but is not inhibited when pericytes are not in contact or close
proximity with the endothelial cells. Furthermore, inhibition
of proliferation decreases as the ratio of endothelial cells to
pericytes increases. No inhibition of growth was noted with
RPE, fibroblast, or kidney epithelial cells exposed to pericytes [51].
In early diabetes, there is not yet enough retinal vessel
damage to result in hypoxia of the retina. At this stage, destructive elements to the retina include hyperglycemia, advanced glycation end-products (AGE), oxidants and protein
kinase C. Pericytes are lost early in diabetic retinopathy, but
at an early stage they can still be producers of VEGF [5658]. Vidro et al. demonstrated that high glucose treatment of
human retinal pericytes in cell culture resulted in a reduction
of viable cell number and an increased production of VEGF
per cell from remaining viable cells. Further, these cells produced significantly more VEGF than TGF2 with increasing
glucose concentration. These effects were lost with the addition of exogenous TGF2 [58].
Both intra and extracellular VEGF protein and mRNA
were found to be increased with exposure to hyperglycemic
media in a rhesus monkey and a rat retinal endothelial cell
line and in primary bovine retinal endothelial cells [59-61].
Secreted VEGF protein was increased by 50% in response to
25nM glucose in the rat retinal endothelial cell line [59].
However, using human umbilical vein endothelial cells,
Yang et al. demonstrated a decrease in VEGF mRNA and
protein secretion with hyperglycemic media. They found that
adding exogenous VEGF to the culture media was protective
against apoptosis [62].
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Increased VEGF production with hyperglycemia appears
to be at least partially induced through transcription factor
specificity protein (Sp1) [59, 63]. Increased insulin exposure
has been found to increase VEGF production. Wu et al.
found in bovine retina endothelial cells that increasing glucose levels attenuated elevated VEGF production that could
be attributed to insulin exposure. In contrast, cells previously
exposed to high glucose insulin exposure decreased VEGF
production [60].
High glucose also acts in vivo through other mechanisms
to increase VEGF production. One of these is the formation
of advanced glycation end-products (AGE) from glucose
attachment to extracellular and intracellular proteins (in cells
without GLUT-4 transport) such as collagen, crystallins, and
enzymes [64]. They develop both in the serum and in the
retina [13]. From the serum, AGE proteins may be transcytosed into endothelial cells, bypassing the blood-retinal barrier
by attachment to the receptor for advanced glycation endproducts (RAGE) and deposited in the vessel wall containing
Table 1.

the endothelial cells and pericytes. AGE proteins have been
found to increase the production of VEGF mRNA and protein in bovine pericytes in vitro and lead to their apoptosis
[56, 57, 65]. Therefore, the increased production of VEGF
from pericytes in diabetes may be significant for early diabetes effects, but may be short-lived due to the imminent demise of pericytes. Increased VEGF mRNA and protein production obtained from lysed endothelial cells has also been
linked to increasing AGE exposure [13, 57, 66]. The sulfonylurea and anti-oxidant gliclazide was found to decrease
both VEGF mRNA and protein in these AGE-exposed
endothelial cells. Other anti-oxidants vitamin E and Nacetylcysteine (NAC) were also found to decrease VEGF
mRNA. Another sulfonylurea glyberide demonstrated no
effect on VEGF production in AGE-exposed endothelial
cells [13]. Gliclazide, vitamin E and NAC inhibited protein
kinase C translocation from the cytosol to membrane fractions in these AGE-exposed cells and gliclazide reduced nuclear factor kappa B (NF-B) binding to the VEGF pro-

Endothelial cell VEGF production Pre-hypoxia.

Stimulus

Condition

Major Findings

References

Co-culture

In vitro

Co-Culture of endothelial cells and pericyte precursors; very little VEGF production
compared to pericytes

Darland et al., 2003

Protein lysates, secreted, and mRNA of VEGF were increased using hyperglycemic
media in rhesus monkey, rat cell lines, and bovine primary endothelial cells.

Wu et al., 2010; Li et al.,
2012; Donovan et al., 2014;

In HUVEC cells, VEGF seemed to protect against apoptosis, but VEGF mRNA and
secreted protein were reduced with higher concentration.

Betts-Obregon et al., 2016

Hyperglycemia

In vitro

Yang et al., 2008

AGE

In vitro

AGE exposure increased VEGF mRNA and protein levels in endothelial cell lysates.

Mamputu et al., 2002; Mamputu, et al., 2004; Shimizu et
al., 2011; Shimizu et al., 2013

ROS

In vitro

Anti-oxidants inhibit AGE induced VEGF mRNA increases in bovine retinal endothelial
cells

Mamputu et al., 2002

Estrogen

In vitro

Estrogen induced a decrease in VEGF and PEDF protein secretion from rhesus monkey
retinal endothelial cells in a dose dependent manner.

Grigsby et al., 2011

Table 2.

Pericyte VEGF production Pre-hypoxia.

Stimulus

Condition

Major Findings

References

Co-culture

In vitro

Co-culture of endothelial cells (EC) and pericyte precursors resulted in a time dependent
increase in VEGF secretion. Co-Culture VEGF production is mediated by TGF . Inhibition of VEGF increased EC apoptosis. These findings suggest that pericyte-derived
VEGF is required for EC survival and stability.

Darland et al., 2003

Hyperglycemia

In vitro

High glucose decreased viable human pericyte cell number, but increased VEGF secretion into cell media (and per cell) in a concentration dependent manner.

Vidro et al., 2008

AGE

In vitro

Bovine retinal pericytes treated with different AGE products showed increased VEGF
mRNA expression in a time dependent manner.

Yamagishi et al., 2002

Human peripheral nerve pericytes treated with different concentrations of AGEs showed
increased VEGF expression.

Shimizu et al., 2011

Human brain pericytes exposed to AGEs showed no concentration dependent change in
VEGF protein level.

Shimizu et al., 2013
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moter. Thus, AGE stimulated expression of VEGF appears
to proceed through an oxidative stress induced protein kinase
C dependent NF-B binding mechanism [13].
3. MÜLLER CELLS
Müller cells extend from vitreous to the outer nuclear
layer, enveloping neurons and blood vessels with their cellular processes serving as an anatomical and functional link
between retinal neurons and other compartments [67, 68].
Müller cells maintain the homeostasis of the extracellular
space composition, aid in recycling of neurotransmitters
(namely glutamate and GABA), release gliotransmitters
(principally glutamate, ATP, and adenosine), provide trophic
factors to neurons, maintain the inner blood-retinal barrier,
regulate the retinal blood flow, provide anti-oxidative support to neurons, act as optical fibers, regenerate 11-cis retinol
during bleaching of cone photoreceptors, buffer potassium,
form neural stem cells in response to injury, produce
pro-inflammatory cytokines in response to infection and
phagocytize fragments of retinal cells and foreign particles
[67, 69-72].
Müller cells are modulators of angiogenesis in proliferative diabetic retinopathy. They secrete PEDF, a potent inhibitor of angiogenesis, as well as VEGF, a potent angiogenesis inducer [73, 74]. Through a balance of VEGF and
PEDF, Müller cells are potentially key regulators of neovascularization of the retina [75].
The importance of Müller cell VEGF production was
confirmed in conditional Muller cell VEGF KO mice generated by mating transgenic Cre recombinase mice with floxed
VEGF mice [76]. This results in a partial (40-60%) reduction
in VEGF secretion by Müller cells. In VEGF-KO mice the
development of the choroid or retina was unaffected. However, when challenged with oxygen-induced retinopathy,
VEGF-KO mice showed a 43.3% reduction in ischemiainduced retinal neovascularization (NV), a 29.6% reduction
of vaso-obliteration, a 33.7% reduction in NV and 35% more
of the tight-junction protein occludin in comparison to WT
controls [77]. In a study by Wang et al. both WT mice and
VEGF-KO mice were made diabetic by streptozotocin (STZ)
injection. Controls were untreated WT or VEGF-KO [44].
Even though VEGF expression by Müller cells was only
partially ablated, immunoblotting of extracts from dissected
retina and vitreous demonstrated a significant reduction
(47.4%) of retinal VEGF levels in diabetic KO mice relative
to WT mice. WT diabetic mice lost tight junction proteins
while VEGF-KO mice retained normal levels. The VEGFKO mice also showed reduced evidence of acellular capillaries, leukostasis, inflammatory biomarkers (ICAM-1, TNF-
and phosphorylated NF-B p65 subunit) and vascular leakage [44]. Thus, Müller cell VEGF plays an essential part in
retinal inflammation during the course of diabetic retinopathy. Four VEGF variants are known to occur in Müller cells
[78]. It was concluded that the predominant type of VEGF
produced by mice Müller cells is VEGF164 [10, 69, 70].
Immuno-histologic analysis of human and rat retinas
show that Müller cells are rich in VEGF receptors. Furthermore, RT-PCR analysis of purified human Müller cells as
well as primary rat Müller cells has revealed mRNA for
VEGFR-1 and VEGFR-2 [79, 80]. Human Müller cells also
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express mRNA for the isoform-specific co-receptor for
VEGF-A neuropilin-1 (NP1) [80]. Müller cells that express
VEGFR-1 or 2 respond to VEGF via a MAPK pathway. An
antagonist to VEGFR-1 and 2, SU5416, inhibited retinal
neovascularization [81]. However, adenoviral expression of
sFlt1 (VEGFR-1) neutralized VEGF initiated apoptosis of
cells in the INL and ONL and reduced a- and b-wave amplitudes of the ERG [5]. To assess autocrine signaling through
VEGFR-2, MIO-M1 Müller cells were used. MIO-M1 is a
spontaneously immortalized human Muller cell line which
retains the normal Müller cell phenotype [82]. When siRNA
was used to suppress VEGF by 94% in these cells, there was
a doubling of Müller cell apoptosis compared to untreated
controls. PCR showed that inhibition of VEGF expression
up-regulated expression of the pro-apoptotic gene Bax but
the expression of anti-apoptotic genes Bcl-2 remained unchanged. Thus the Bax/Bcl-2 ratio was increased. These results confirm constitutive expression of VEGF is needed not
only for survival of photoreceptor and retinal ganglion cells,
but also for survival of Müller cells themselves [5]. In a recent study of streptotocin-treated conditional VEGFR-2 KO
mice, loss of the VEGFR-2 led to a decreased census of
Müller cells, reductions in ERG amplitude and loss of rod
and cone photoreceptors [30].
Most studies have found that hyperglycemia increases
secretion of VEGF in Muller cell lines [83]. Using hyperglycemia with MIO-M1 cells Aldarwesh et al. found a statistically significant increase in VEGF mRNA at 24 hours compared to normal glucose. Secreted VEGF into the conditioned media measured by ELISA increased at 24 and 48
hours, but did not achieve statistical significance until 72
hours [83]. Vellanki et al. found an increase in cell number,
but an insignificant difference in per cell VEGF secretion at
24 hours with both MIO-M1 and rMC-1 cells comparing
physiological (5.5 nM) to high (30 mM) glucose [84]. Müller
cell VEGF expression is increased early in humans during
non-proliferative DR [85]. Aquaporin 4 (AQP4), a Müller
cell and astrocyte channel protein and the ratio of AQP4 to
aquaporin 1 (AQPA1), another glial cell channel protein, is
significantly increased in the aqueous humor of humans with
pre-clinical DR, indicating early Müller cell activation [86].
The mechanisms by which hyperglycemia causes gliosis and
up-regulates VEGF are currently under investigation in Muller cells. A study by Schrufer et al. using rat and human
Müller cell lines (TR-MUL and MIO-M1) showed that an
increase in VEGF is due to a cap-independent mRNA translation mediated by increased expression of and decreased
phosphorylation of eukaryotic initiation factor 4E (4E-BP1).
This is achieved by an increased sequestration of eIF4 by
4E-BP1. Ye et al. reported that after Müller cells are stimulated with high glucose, phosphorylation of ERK1/2 occurs.
Thus, the ERK1/2 pathway might also be involved in the
increase of VEGF secretion observed in hyperglycemia. Sun
et al. implicated X-linked inhibitor of apoptosis protein
(XIAP) as a factor in increased expression of Muller cell
VEGF in hyperglycemia by proving that embelin, a XIAP
inhibitor, decreased VEGF expression in cultured rat Müller
cells under hyperglycemic conditions. The authors suggested
that XIAP may regulate VEGF through a regulatory network
involving NFB p65, p38, TNF-, uPA, CREB, IL-1, ER,
Stat3, and HCAM [87]. A study by Devi et al. suggested that
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Müller cells exposed to hyperglycemia increase their VEGF
secretion through a signaling pathway involving autophagy.
The authors proved that rMC-1 cells exposed chronically to
high glucose conditions increase their expression of TXNIP,
a pro-oxidative stress protein. Sustained high glucose conditions lead to an increase in ROS, leading to ER stress as well
as an increase in HIF-1 levels accompanied by a decrease
of ATP. However, cell viability did not increase with high
glucose conditions. Therefore, autophagy was activated as a
cell survival mechanism. Excessive and continuous autophagy induces cell apoptosis, which induces Müller cells to
express pro-inflammatory genes, including VEGF [88].
Zhong, Y., et al. found that ER stress induced by hyperglycemia also leads to the activation of activating transcription
factor 4 (ATF4) that results in elevated ICAM-1 and VEGF
proteins in Müller cells through a pathway involving c-Jun
N-terminal Kinases (JNK) [89].
Dennis et al. found that hyperglycemia increased both
VEGF and a ubiquitous protein regulated in DNA damage
and development (REDD1) in retinal homogenates from
STZ-treated rats with the effects cancelled by normalizing
serum glucose with the anti-oxidant and glucose receptor
inhibitor, phlorizin. In hyperglycemic Müller cells (human
MIO-M1 and rat TR-MUL), REDD1 plays a permissive role
in VEGF translation by repressing akt/mTORC1 phosphorylation of 4E-BP1, allowing it to dissociate from the capbinding protein elF4E and slow cap-dependent translation.
Cap-independent translation then ensues to augment VEGF
production. After 4 weeks of STZ-treatment wild type mice
showed increased expression of VEGF and the proinflammatory TNF-. These increases did not occur in
REDD1-KO mice. Thus REDD1 is necessary for hyperglycemic increases in Müller cell VEGF [90].
In MCT cells, a mouse renal proximal tubule cell line, it
has been shown that angiotensin II promotes 4E-BP1 phosphorylation, thus up-regulating VEGF translation. Furthermore, hyperglycemic conditions increase synthesis of angiotensinogen, a precursor of angiotensin. Thus, in MCT cells,
hyperglycemia might lead to an increase in angiotension II
causing more 4E-BP1 phosphorylation and thus more VEGF
expression [91, 92]. Müller cells have angiotensin receptors
and both angiotensin converting enzyme (ACE) and angiotensin II are elevated in vitreous samples of patients with
diabetic retinopathy. Moreover, cultured human Müller cells
contain mRNA for renin, angiotensinogen, ACE and angiotensin receptor type 1 [93]. Both valsartan, an angiotensin I
receptor antagonist, and PD123319, an angiotensin II receptor antagonist, decreased VEGF expression [94].
Advanced Glycation end-products (AGE) result from hyperglycemia and are associated with diabetic retinopathy in
human patients and animal models of experimental diabetes.
AGEs worsen oxidative stress and inflammation by interacting with RAGE receptors on susceptible cells, including
Müller cells [95-97]. Müller cell VEGF expression and secretion follows RAGE activation. Early reports showed a
relationship between AGEs and Müller cell VEGF. PCR and
western blots from cultured Müller cells showed that VEGF
mRNA and protein were increased by AGEs. Vitreous sampled from PDR patients showed significantly higher AGE
and VEGF than vitreous from controls without diabetes [95].
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Pathogenic effects of diabetes in STZ-treated rats were
blocked by pyridoxamine, an inhibitor of AGEs and advanced lipoxidation end products (ALEs) [98].
In a study of hyperglycemic and hyperlipidemic mice,
ERG, immunohistochemistry, RT-PCR, autoFL and ELISA
were employed to study AGE and RAGE. AGEs were associated with the footplates of RAGE-positive Müller cells and
were increased in the extracellular matrix in hyperglycemic
mice. RAGE mRNA transcripts were highest in Highglucose High Lipidemic mice compared to normal mice.
RAGE-induced formation of acellular capillaries and pericyte ghosts was reduced by application of soluble RAGE
(sRAGE) that competitively inhibits RAGE function [99].
AGE, ALE, giant fibrillary acidic protein (GFAP) and hemeoxidase were studied in normal control rats, diabetic rats (via
STZ) and diabetic rats w/pyridoxamine. Pyridoxamine
treatment achieved significant reduction in AGEs, ALEs,
GFAP and heme-oxidase in ganglion cells and the inner
plexiform layer (IPL); moreover, abnormal positioning of the
K+ channel protein (Kir4.1) and aquaporins were also reduced by pyridoxamine [96].
Zong et al. (2010) studied RAGE, the RAGE ligand
S100B and GFAP in retinal cryosections of STZ and control
rats. RAGE increased in the experimental diabetes. They
also exposed M10-M1 Muller cells to normal and 5x glucose
media, with the latter causing increased GFAP, RAGE and
S100B. Use of sRAGE or a si-RAGE protocol blocked
VEGF increases observed in high glucose. It was also suggested that RAGE activates a MAPK pathway [97]. In a related study, STZ-treated and normal rats fed a normal diet
were compared to the same groups fed a high fat diet. The
number of pericytes declined in both diabetic groups, but in
the diabetic rats fed a high fat diet, markers for diabetic
complication (RAGE, GFAP, VEGF and TNF-) increased
significantly [100].
Inevitably, a RAGE-/- mouse was developed for comparison to wild-type (WT) mice. Both were given either sham
saline injections or injections of STZ. The WT mice developed DR and increased concentrations of RAGE at 12 weeks
but not at 24 weeks. GFAP was increased in WT, but importantly, RAGE -/- mice were protected from this effect [101].
Clearly, RAGE binding by AGE ligands in experimental
diabetes activates Muller cells as evidenced by increased
secretion of GFAP and VEGF. Potential treatments can now
include inhibition of the AGE/RAGE signaling pathway.
4. MICROGLIA AND ASTROCYTES
Microglia are the resident macrophage of the retina.
Their interaction with other retinal cells has been postulated
to play a key role in DR [102]. In early diabetes circulating
VEGF production and local production of ICAM-1 and
VCAM can increase the exposure of microglia to inflammatory cytokines transitioning microglia into an activated, i.e.
amoeboid, state [102-104]. High glucose, AGE, or ROS can
perpetuate this state.
De-Oliveria-Simoes-Pereria et al. found that when rat
retinal cells were cultured in high glucose, purinergic P2
receptors in microglia were up-regulated, causing a calcium
influx and release of microglial associated pro-inflammatory
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Müller cell VEGF production Pre-hypoxia.

Stimulus

Condition

Major Findings

References

Hyperglycemia

In vitro

Hyperglycemic treatment for 24 hours resulted in a 4-fold increase in VEGF mRNA
and a 2.6 fold increase in secreted protein production at 72 hours using MIO-M1
(human Müller cell line) and retinal explants.

Alderwash et al., 2016

In vitro

Hyperglycemia increased MIO-M1cell number, but no significant change in per cell
VEGF secretion at 24 hours with MIO-M1 or rat (rMC-1) cells.

Vellanki et al., 2016

In vitro

In cultured primary rat Müller cells, hyperglycemia elevated VEGF secretion. This
expression was reduced by an inhibitor-U0126. U0126 stopped phosphorylation of
ERK .

Ye et al., 2012

In vitro

Embelin an inhibitor of XIAP (blocks cells from entering apoptosis), normalized the
increased VEGF protein production in rat Müller cells attributed to hyperglycemia.

Sun et al., 2013

In vivo and
in vitro

VEGF mRNA levels and HIF-1 activity were increased in a rat Müller cell line due to
hyperglycemia, this change was linked to thioredoxin interacting protein (TXNIP)

Devi et al., 2012

In vivo and
in vitro

Regulated in development and DNA damage 1 (REDD1) was necessary for hyperglycemia induced elevated VEGF protein in STZ rats and mRNA in rat TR-MUL cells.

Dennis et al., 2014

In vivo and
in vitro

Inhibition of activating transcription factor 4 (ATF4) in rat Müller cell line (rMC-1)
and C57BL/6 J mice decreased VEGF production.

Zhong et al., 2011

In vivo

Frozen sections of eyes with diabetes, but without PDR showed VEGF expression in
Müller cell distribution.

Amin et al., 1997

In vivo

Early activation of Müller cells is shown in pre-clinical DR.

Vujosevic et al., 2015

In vivo and
in vitro

Müller cell-VEGF mRNA expression was increased early (3 weeks) in STZ rats through
cap-independent translation. Similar results were observed in cultured Müller cells.

Schrufer et al., 2010

In vivo and
in vitro

Hyperglycemia upregulates angiotensinogen. Angiotensin II promotes 4E-BP1 phosphorylation which upregulates VEGF. VEGF expression was decreased with angiotensin I and II receptor antagonist in rat retina.

Kida et al., 2003; Zhang et
al., 2004; Schrufer et al.,
2010; Ye et al., 2012

In vivo and
in vitro

AGE increased VEGF mRNA and protein expression in cultured Müller cells. Pyridoxamine (AGE inhibitor) blocked development of retinopathy in diabetic rats Elevated VEGF levels in hyperglycemia were inhibited by blocking/absence of RAGE.

Hirata et al., 1997; Stitt et
al., 2002; Zong et al., 2010;
McVicar et al., 2015;

Angiotensin/
Hyperglycemia
AGE

mediators seen in DR [105]. Molecules released by activated
retinal microglia include glutamate, proteases, leukotrienes,
IL-1, IL-3, IL-6, TNF-, VEGF, lymphotoxin, macrophage
inflammatory protein 1 (MIP-1), matrix metalloproteinases
(MMPs), caspase 3, and ROS [103, 106]. TNF- leads to the
production of ICAM-1 and VCAM thus further contributing
to retinal vascular leakage and creating a circle of inflammation and VEGF production [107].
Astrocytes (AC) migrate from the optic nerve head during development. Throughout life, they are found in the retinal nerve fiber and ganglion cell layers and the intraocular
portion of the optic nerve [86, 108-111]. During development, astrocytes produce VEGF and may play some role in
inner retinal vasculature formation [112-115]. Adult mammal AC are densely packed near blood vessels. They serve
several functions such as regulation of blood flow, conversion of glucose to lactate, and removal of toxins from retinal
neurons [116, 117]. Their density is dependent on the thickness of the nerve fiber layer, being higher in the superior and
inferior arcades and less at the macula and the ora [110]. It is
believed that astrocytes play a role in stabilizing retinal vasculature, but in response to hypoxia HIF-1 stimulate VEGF

production in the adult, creating pathological neovascularization such as in PDR [112, 113, 115]. It is well established
that astrocytes produce VEGF during diabetic retinopathy
[29, 118]. What is less clear is that stimuli other than hypoxia
may also activate astrocyte dysfunction and VEGF production.
Using hyperglycemia as a stimulus, Shin et al. found increases
in inflammatory cytokines and activation of pathways linked
to VEGF production, but they did not specifically test for
VEGF mRNA or protein production [119-121].
5. RETINAL PIGMENT EPITHELIAL CELLS
The retinal pigment epithelium (RPE) is a monolayer of
cells that constitute the outer blood-retinal barrier (BRB).
The main functions of RPE cells are the following: supply
nutrients to photoreceptors and maintain ion homeostasis in
the sub-retinal space, absorb scattered light in order to protect against photooxidation, re-isomerize all-trans-retinol
into 11-cis-retinal as part of the visual cycle, phagocytize
shed photoreceptor membranes, secrete a variety of signaling
molecules essential for the structural integrity of the retina
and maintain the inner eye as an immune privileged space
[59, 122-125]. RPE cells are capable of acting as oxygen and
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metabolic sensors that regulate angiogenesis in response to
changing local environment [122]. It is known that the production of VEGF by RPE cells constitutes an important step
for the development of DR, clarifying the stimulus for its upregulation is extremely important in understanding DR
pathogenesis.
It is known that hyperglycemia instigates a series of biochemical changes that ultimately lead to vascular dysfunction, increasing vascular permeability and capillary rarefaction (a decrease in the number of perfused capillaries in an
area of tissue). In ARPE-19, a human RPE cell line, it has
been demonstrated that hyperglycemic conditions affect cell
growth, cell differentiation and cell functions. RPE cells cultured in 18mM glucose proliferate at a considerably faster
rate than cells cultured in euglycemic conditions and assume
a more elongated shape [126]. Hyperglycemia itself is considered a potent stimulus for VEGF secretion by RPE. It has
been demonstrated that culturing primary human RPE or
ARPE-19 cells in high glucose up-regulates VEGF mRNA
and protein expression [123, 126]. Chang et al. suggested
that high glucose conditions induce carbohydrate response
element binding protein (ChREBP) to activate HIF-1, leading to the increased VEGF expression [124]. Additionally,
Vogt et al. reported that ARPE-19 cells cultured in high glucose conditions increased bone morphogenetic protein 4
(BMP-4) secretion and that BMP-4 increased VEGF secretion through unknown transduction pathways [127]. Furthermore, Wang et al. demonstrated that RPE cells upregulate integrin-linked kinase (ILK) in high glucose conditions and proposed that the ILK pathway may be involved in
the response of RPE cells to hyperglycemia [125].
Even though several pathways seem to influence VEGF
hyperglycemia mediated induction in RPE cells, the main
pathway involved may be the O-linked b,N-acetylglucosamine (O-GlcNAc) posttranslational modification and its effect on the transcription factor Sp1. O-GlcNAc glycosylation
promotes Sp1 stability, localization to the nucleus and transcriptional activity, resulting in increased VEGF expression.
Because O-GlcNac is produced by the hexosamine biosynthetic pathway, O-GlcNac glycosylation and Sp1 activity are
up-regulated in hyperglycemic conditions. Donovan et al.
managed to successfully abrogate VEGF up-regulation in
ARPE-19 cells by inhibiting O-GlcNAc posttranslational
modification of Sp1. Thus, the proposed mechanism for
VEGF-A up-regulation in hyperglycemic conditions is the
increase in Sp1 activity through the pan-cellular increase of
O-GlcNAc glycosylation. Significantly, RPE cells in which
O-GlcNAc glycosylation or Sp1 transcription factor are inhibited are glucose insensitive but do not decrease the basal
VEGF-A production, making inhibitors of the enzyme OGlcNAc transferase an attractive potential therapy for diabetic retinopathy [59].
High glucose conditions may not induce VEGF expression directly as potently as the other biochemical changes.
One such metabolic alteration is the production of AGEs. It
has been demonstrated that AGEs induce RPE cells to upregulate several cytokines and growth factors, such as
VEGF, IL-8 and monocyte chemoattractant protein - 1
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(MCP-1), which might be important for DR pathogenesis
[128, 129]. Incubation of human RPE with AGEs alone results in a 5-fold increase of VEGF mRNA production. This
increase in VEGF mRNA by AGE exposure is blocked by
the antioxidants N,N9-dimethylthiourea (DMTU) and Nacetylcysteine (NAC), implicating reactive oxygen intermediates (ROI) as mediators for this response [130] Additionally, the RAGE-mediated up-regulation of VEGF secretion by ARPE-19 cells seems to be largely dependent on NFB [131].
Metabolic abnormalities found in chronic hyperglycemia
are ROS production, increased flux through the polyol pathway, and excessive protein glycation [132]. RPE cells treated
with either tert-butylhydroperoxide (tBH), buthionine sulfoxime (BSO) or oxidized low density lipoprotein (oxLDL)
and thus under oxidative stress have shown an increase of
VEGF secretion [133-137]. Furthermore, on ARPE-19 cells
treated with 4-hydroxynonenal (HNE) or malondialdehyde
(MDA), it was observed that lipid peroxidation products
caused an increase of total VEGF-A protein secretion into the
culture medium [138]. Li et al. proposed that the high VEGF
secretion observed in high glucose conditions was due to the
oxidative stress induced in RPE cells by hyperglycemia that
activated the JAK-2/STAT3 pathway [139].
Not only does oxidative stress induce VEGF expression
in RPE cells, but it also contributes to inflammation and dysregulation of the complement system. In ARPE-19 cells with
increased intracellular ROS levels induced by cigarette
smoke concentrate (CSC) or H2O2, premature senescence
with increased VEGF, IL-6 and IL-8 expression and downregulated complement factor H (CFH) were demonstrated
[140]. Similarly, hydroquinone-treated human RPE cultures
exhibited, apart from increased levels of VEGF, higher IL-12
and IL-10 levels and lower MCP1 and pigment epithelial
derived factor (PEDF) levels [141, 142]. Another cigarette
smoke component acrolein, an aldehyde, has also been found
to increase VEGF production in ARPE-19 cells [143].
Thurman et al., propose that since oxidatively stressed
ARPE-19 cells show decreased levels of complement decayaccelerating factor (DAF), CD59 and CFH, oxidative stress
induction of VEGF expression might be mediated through
complement activation [144]. Additionally, complement
activation in RPE cells increases MMP-2 and MMP-3 that
further increase VEGF and decrease PEDF [145].
Chronic inflammation observed in patients with DR is a
key component of pathologic neovascularization [122]. Protein and mRNA levels of VEGF in human RPE cells incubated for 24 h with IL-1 (a pro-inflammatory molecule)
were up-regulated two- to four-fold. This was signiﬁcantly
suppressed by adding IL-4 (an anti-inflammation factor)
[123]. Likewise, the inflammatory molecules IFN, IL-6 and
TNF have been shown to increase ARPE-19 VEGF secretion by 3.9, 1.22, and 1.82X, respectively [146]. A study
using a mix of inflammatory cytokines containing
IFN,TNF- and IL-1 demonstrated that inflammation not
only increases VEGF-A secretion in human RPE cells by 10fold but also increases VEGF-C expression by 9-fold [147].
In summary, hyperglycemia seems to be the main driving
force for the up-regulation of VEGF secretion by RPE cells
in pre-hypoxic DR by direct and indirect mechanisms.
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Retinal pigment epithelial cell VEGF production Pre-hypoxia.

Stimulus

Condition

Major Findings

References

Hyperglycemia

In vitro

mRNA and protein levels of VEGF were increased in hRPE cells incubated in
hyperglycemic conditions. Such response was shown to be suppressed by addition
of IL-4 or melanin and by knocking down ILK gene expression. Additionally, the
O-GlcNAcylated transcription factor Sp1 seemed to be involved.

Klettner et al., 2015; Wang et
al., 2012; Donovan et al., 2014;
Grigsby et al., 2012; Heimsath et
al., 2006

AGE

In vivo and
in vitro

Injection of AGEs in rat and rabbit eyes increased VEGF mRNA levels. Also,
hRPE cultured with AGEs up-regulated VEGF protein expression in a time and
dose dependent manner. This expression was further blocked by antioxidants
DMTU and NAC.

Lu et al., 1998

Oxidative
Stress

In vitro

In hRPE cells, VEGF expression was up-regulated following exposure to TBHP,
BSO, hydroquinone, high glucose conditions (resulting in ROS production), and
H2O2 with human serum (as a source of complement proteins). ARPE-19 and porcine RPE cells exposed to tBH increased VEGF expression, possibly through p38
and ERK pathways. In APRE-19 cells, addition of oxLDL, bafilomycin A1 (to
block lysosomal function), lipid peroxidation products HNE and MDA and H2O2
followed by CSC (as inductors of senescence) resulted in VEGF up-regulation.

Rabin et al., 2013; Sreekumar et
al., 2006; Li et al., 2012; Cao et
al., 2013; Pons et al., 2011;
Thurman et al., 2009; Kannan et
al., 2006; Klettner et al., 2009;
Li et al., 2014; Bergmann et al.,
2011; Marazita et al., 2016

Inflammatory
proteins

In vitro

In hRPE and ARPE-19 cells, IFN, IL-6, and TGF increased VEGF mRNA
expression. The pathway involved in INF up-regulation of VEGF is dependent
on PI3K/mTOR. In hRPE cells, the exposure to a mix of IFN- + TNF + IL-1
resulted in an increase of VEGF and up-regulation of NF-B and JAK-STAT pathways. Furthermore, addition of TGF-1, TGF-2, TGF-3, IL-1ß, TNF- and MMP9 increased VEGF secretion. ARPE-19 cells exposed to C5a up-regulate VEGF
secretion.

Liu et al., 2010; Nagineni et al.,
2012; Cortright et al., 2009; Bian
et al., 2007; Nagineni et al.,
2003; Hollborn et al., 2007

Coagulation
factors

In vitro

In hRPE cells, FXa and thrombin upregulated VEGF mRNA and protein
expression.

Hollborn et al., 2012; Bian et al.,
2007

Insulin

In vivo and
in vitro

Insulin increased VEGF mRNA levels in rat RPE cell layers, and in cultured hRPE.

Lu et al., 1999

6. IN-VITRO VEGF PRODUCTION AND SECRETION
BY RETINAL CELLS
It is of particular interest to distinguish between VEGF
production which includes mRNA and protein synthesis and
VEGF secretion, which denotes the release of synthesized
VEGF from VEGF producing cells (Fig. 1). Although many
reports focus on VEGF synthesis by retinal cells in vivo and
in vitro, only a few references have provided quantitative
insights on VEGF secretion. The latter is rather difficult to
assess in-vivo as secreted VEGF is quickly diffused from
source to target or removed by circulation. However, the
secretion of VEGF can be readily accessed in-vitro by examining VEGF levels in cell media of cultured retinal cells.
Table 5 summarizes data on the in-vitro secretion of VEGF
from four types of retinal cells grown in normal and high
glucose for 24 hours. Consistent with reports on retinal
VEGF producing cells, Müller cell and RPE secreted higher
levels of VEGF (fg VEGF per cell) than retinal endothelial
cells and retinal pericytes in both normal (5.5mM) and in
high (18 or 30mM) glucose conditions (Table 5). Although
high glucose induced a significant increase (from 40-185%)
in VEGF secretion (pgVEGF/cell) from retinal RPE, retinal
endothelial cells and pericytes, at 24 hours, it did not induce
an increase in VEGF secretion per Müller cell. This is a
novel observation which requires further investigation as
high glucose is associated with higher levels of VEGF synthesis in Müller cells (see Table 3).

RPE

MC

  PC
BV

AC
BV

PC
MC

EC

MG

AC

Fig. (1). VEGF-secreting cells within the retina. VEGF, indicated
by . Legend: RPE – Retinal Pigment Epithelium PC - Pericyte,
AC – Astrocyte, MG – Microglia, EC - Endothelial Cell, MC –
Muller Cell, BV – Capillary.
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In vitro VEGF secretion (fgVEGF/cell) into the conditioned media by retinal cells in normal glucose (NG; 5.5 nM) and in
high glucose (HG; 18 or 30 mM). Conditioned media were collected after incubation in NG or HG for 24 hours. VEGF
was measured by ELISA.

Retinal Cell Type

Cultured Cell Source

VEGF Secretion
(fg/cell) in NG

VEGF Secretion
(fg/cell) in HG

% change of VEGF per
cell (NG to HG)

Human Retinal Pericytes (HRP) [148]

Primary

1

2

100

Human Retinal Pigment Epithelium
(ARPE-19) [126]

Spontaneously

5

7

40

Rhesus Monkey Retinal Endothelial Cells
(RhREC) [61]

Spontaneously

0.7

2

185

7.3

6.1

-20’

Human Müller Cells (MIO-M1) [84]

Transformed

Transformed
Spontaneously
Transformed

(‘ not statistically significant)

CONCLUSION
The synthesis and secretion of VEGF is an integral part
in the process of DR and occurs for multiple reasons. While
typically associated with angiogenesis and hypoxia, VEGF is
synthesized and secreted by multiple retinal cell types in
both the early and late stages of DR. One must remember
that VEGF secretion related to hyperglycemia, AGE and
ROS still occur during the hypoxic stages of DR adding to
the total VEGF load during PDR. Excellent work by Watkins
et al. compare and quantify VEGF production in various
cells during hypoxic stimuli, but no such work exists of
VEGF production of retinal cells during hyperglycemia,
AGE, PKC stimulation, or ROS [15]. Few doubts exist that
even at these early non-hypoxic stages of DR that Muller
cells are a significant source of VEGF. Proximity of cells
certainly plays a role in the actions they confer. Pericytes are
most closely associated with endothelial cells, but may be
short lived in DR development, thus the paracrine secretions
of other retinal cells are important [48, 49].
Retinal pigment epithelium is well known as a major
producer of VEGF in age-related macular degeneration. It
has also been found to produce VEGF in diabetes in response to hyperglycemia, AGE, ROS and hypoxia. Since
most of the anoxia in DR is in the inner retina and RPE is
located near choroidal circulation a question remains, does
RPE significantly increase its VEGF production beyond nonhypoxic levels as hypoxia becomes a factor in the diabetic
retina?
The addition of estrogen into the normoglycemic conditioned media of rhesus retinal endothelial cells decreases the
ratio of PEDF/VEGF secretion into the media [149]. If similar effects can be found on estrogen effects of hyperglycemia
on PEDF/VEGF secretion of retinal endothelial cells it may
offer an explanation as to the worsening of DR during pregnancy. Human retina contains estrogen receptors [150]. The
temporary progression of DR during pregnancy is well established; 6.3% of those with mild NPDR and 29% of those
with moderate NPDR will develop PDR during pregnancy
[151]. Pre-puberty seems to offer somewhat of a grace period to the development of DR and males seem to have
higher incidences of advanced retinopathy [149, 152]. It ap-

pears that sex hormones play a role in DR, but how they affect VEGF production in vivo is not clear [149, 153].
Hyperglycemia appears to be the trigger that sets the
whole process in motion and AGE, PKC phosphorylation,
osmolarity changes and ROS exposure evolve from it. While
the levels of VEGF produced by endothelial cells, pericytes,
astrocytes, microglia, Müller cells and RPE are less in the
non-hypoxic retina than in hypoxia all respond to hyperglycemia-associated events and contribute to increases in VEGF
[11, 83]. VEGF secretion may be protective to some retinal
cells, but it also may subsequently contribute to the cumulative damage from hyperglycemia. The increased permeability resulting from retinal VEGF in early diabetes exposes the
retina to AGE, ROS and inflammatory molecules that presage more severe stages of DR [31, 102]. While much work
has been done in this area, many questions persist.
Information on VEGF production in the retina may lead
to new approaches on treatment and intervention of neovascular diseases in the retina including DR. For example, novel
and effective pharmacological interventions may be directed
toward attenuating the production of VEGF from major producers such as Muller cells and pigment epithelial cells. Detailed biochemistry on the molecular pathways of VEGF
production will provide invaluable opportunities to investigate inhibition of cellular processes leading to VEGF production and release under pathological conditions.
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